Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AcelRx Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRX
Nasdaq
2834
http://www.acelrx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
- May 20th, 2022 4:49 pm
Why AcelRx Pharma Shares Are Trading Higher Today?
- May 19th, 2022 3:56 pm
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
- May 19th, 2022 12:30 pm
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
- May 16th, 2022 12:45 pm
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
- May 16th, 2022 11:30 am
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
- May 12th, 2022 9:35 pm
Organogenesis (ORGO) Q1 Earnings Lag Estimates
- May 10th, 2022 9:35 pm
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
- May 10th, 2022 12:30 pm
AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022
- May 9th, 2022 11:30 pm
AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program
- Apr 27th, 2022 12:00 pm
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022
- Apr 25th, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
- Apr 21st, 2022 12:30 pm
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
- Mar 31st, 2022 8:10 pm
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
- Mar 29th, 2022 5:08 pm
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
- Mar 10th, 2022 10:15 pm
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
- Mar 10th, 2022 9:01 pm
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
- Mar 3rd, 2022 9:05 pm
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
- Feb 1st, 2022 1:30 pm
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven?
- Jan 31st, 2022 9:24 am
Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ...
- Jan 27th, 2022 6:38 pm
Scroll